Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, specializing in the development of novel therapies for metabolic and endocrine disorders. Focused on creating first-in-class or best-in-class treatments, Viking's research leverages its deep expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
Viking's pipeline includes three main compounds currently in clinical trials. VK2809, a selective thyroid hormone receptor beta agonist, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Recent data from a Phase 2b VOYAGE study showed that VK2809 achieved both its primary and secondary endpoints, demonstrating significant reductions in liver fat content and improvements in fibrosis and NASH resolution over a 52-week treatment period.
The company is also advancing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being developed for the treatment of metabolic disorders such as obesity. Phase 1 and 2 trials have indicated promising efficacy and safety profiles, with significant reductions in body weight observed in treated patients. Viking is evaluating both subcutaneous and oral formulations of VK2735, aiming to enhance patient convenience and expand market opportunities.
In the realm of rare diseases, Viking is developing VK0214, a selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). Currently in a Phase 1b clinical trial, VK0214 has shown potential benefits in treating the adrenomyeloneuropathy (AMN) form of X-ALD.
Financially, Viking reported a strong cash position of $963 million as of March 31, 2024, following a public offering of common stock. The company's strategic focus on advancing its clinical programs, coupled with its robust financial health, positions it well for future growth and development.
For more information, please visit Viking Therapeutics' website.
Viking Therapeutics announced final 52-week results from its Phase 2b VOYAGE study of VK2809 in NASH/MASH patients. The drug achieved primary and secondary endpoints with significant liver fat reductions ranging from 37% to 55% at Week 52. NASH resolution rates were 63-75% in treated groups versus 29% for placebo. Patients showed fibrosis improvement of 44-57% compared to 34% for placebo. The drug demonstrated promising safety profile with 94% of treatment-related adverse events being mild or moderate. Additionally, VK2809 showed 20-25% placebo-adjusted reductions in LDL-C and improvements in other cardiovascular markers.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, will present results from its Phase 2b clinical trial of VK2809 at the 75th Liver Meeting® 2024. The study focuses on patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH). The oral presentation is scheduled for November 19, 2024, at the San Diego Convention Center. The trial, titled 'Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial,' will be presented by Dr. Rohit Loomba, Director of the NAFLD Research Center and Professor of Medicine at the University of California, San Diego.
Viking Therapeutics presented new clinical data from its VK2735 obesity program at ObesityWeek® 2024. The oral tablet formulation showed up to 8.2% weight loss from baseline (6.8% placebo-adjusted) after 28 days of dosing, with effects persisting up to Day 57. The subcutaneous formulation demonstrated up to 14.7% weight loss after 13 weeks in the VENTURE Phase 2 study, with maintenance effects lasting up to 7 weeks post-treatment. Both formulations showed encouraging tolerability with mainly mild adverse events. The company plans to discuss the injectable VK2735's clinical path with FDA and initiate a Phase 2 study for the oral formulation by year-end.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in four major investor conferences in November 2024. The company will attend the Truist Healthcare Conference in New York (Nov 7) for a fireside chat, the UBS Global Healthcare Conference in Rancho Palos Verdes (Nov 11-14), the Stifel Healthcare Conference in New York (Nov 18-19) with a corporate presentation, and the Jefferies London Healthcare Conference (Nov 19-21).
Management will participate in one-on-one meetings at all events. A live webcast of the Stifel presentation will be available through Viking's website, with a replay accessible afterward in the Investors & Media section.
Viking Therapeutics (NASDAQ: VKTX) announced two upcoming presentations at ObesityWeek® 2024 featuring clinical data from their VK2735 obesity program. The presentations will showcase results from: 1) The Phase 2 VENTURE trial evaluating a 13-week subcutaneous treatment of VK2735 in obese subjects, and 2) A Phase 1 multiple ascending dose (MAD) trial testing an oral formulation administered daily for 28 days. VK2735 is a dual agonist targeting GLP-1 and GIP receptors for metabolic disorders treatment. Both presentations will be delivered by Dr. Joel Neutel at the Henry B. Gonzalez Convention Center on November 3, 2024.
Viking Therapeutics reported Q3 2024 financial results and pipeline updates. The company ended Q3 with $930 million in cash. Key highlights include planned End-of-Phase 2 Meeting for subcutaneous VK2735 obesity treatment in Q4 2024, expected initiation of Phase 2 study for oral VK2735 in Q4 2024, and positive Phase 1b results for VK0214 in X-ALD. The company reported a net loss of $24.9 million ($0.22 per share) for Q3 2024, compared to $22.5 million ($0.23 per share) in Q3 2023. R&D expenses increased to $22.8 million from $18.4 million year-over-year.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, has announced it will release its financial results for the third quarter of 2024 after market close on Wednesday, October 23, 2024. The company will host a conference call to discuss these results and provide general corporate updates at 4:30 p.m. Eastern Time on the same day.
To participate in the conference call, U.S. callers can dial (844) 850-0543, while international callers should use (412) 317-5199. A telephone replay will be available until October 30, 2024, accessible by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S., using the replay access code #9473630. The call can also be accessed via webcast on Viking's website, with an archive available for 30 days.
Viking Therapeutics announced positive results from its Phase 1b clinical trial of VK0214, a novel TRβ agonist, in patients with X-linked adrenoleukodystrophy (X-ALD). The study showed VK0214 to be safe and well-tolerated with once-daily dosing over 28 days. Significant reductions were observed in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids compared to placebo.
Key findings include:
- Significant reductions in mean VLCFA levels at both 20 mg/day and 40 mg/day doses
- Reductions in C26:0-LPC, a key diagnostic marker
- Decreases in LDL-C, ApoB, and Lp(a) levels
- Mild to moderate treatment emergent adverse events
- Lower incidence of gastrointestinal adverse events in VK0214-treated subjects (11%) compared to placebo (33%)
The company views these results as encouraging and plans to explore next steps for VK0214 in X-ALD treatment.
Viking Therapeutics (NASDAQ: VKTX) announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6, 2024, in New York City. CEO Brian Lian, Ph.D., will be the featured speaker in a fireside chat scheduled for September 4, 2024, from 1:50 – 2:25 p.m. Eastern at the New York Marriott Marquis.
The event will include Dr. Lian's participation in 1-on-1 meetings and a live webcast of the fireside chat. Investors can access the webcast through Viking's website in the Investors & Media section under Webcasts. A replay will be available post-conference. Viking Therapeutics is a clinical-stage biopharmaceutical company focusing on developing novel therapies for metabolic and endocrine disorders.
Viking Therapeutics (NASDAQ: VKTX) reported Q2 2024 financial results and provided corporate updates.
Key points include:
- VK2735: Advancing to Phase 3 for obesity after successful Phase 2 outcomes; Phase 2 oral study to begin in Q4 2024.
- VK2809: Positive biopsy results in NASH/MASH; End-of-Phase 2 meeting planned for Q4 2024.
- VK0214: Phase 1b study completed enrollment for X-ALD; data expected in H2 2024.
- Financials: Net loss of $22.3M ($0.20 per share) in Q2 2024 versus $19.2M ($0.19 per share) in Q2 2023. Cash and equivalents at $942M as of June 30, 2024.
Viking will host a conference call at 4:30 p.m. ET today to discuss these results.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
What is the focus of Viking Therapeutics, Inc.?
What are the main compounds in Viking's clinical pipeline?
What recent achievements has Viking Therapeutics reported?
What financial condition is Viking Therapeutics currently in?
What are the potential treatments being developed by Viking for metabolic disorders?
How does VK2735 work?
What is VK0214 targeting?
What significant clinical milestones has VK2809 achieved?
How is Viking Therapeutics funded for its operations?
Where can I get more information about Viking Therapeutics?
